Details of the Drug Formulation (DFM)
General Information of DFM (ID: F18991) | |||||
---|---|---|---|---|---|
Name |
Rifaximin 200 mg tablet
|
||||
Company |
Salix Pharmaceuticals
|
||||
Active Pharmaceutical Ingredient (API) | Rifaximin | API Info click to show the detail info of this API | |||
Hepatic encephalopathy | ICD-11: DB99 | Approved | |||
Drug Inactive Ingredient (DIGs) | |||||
DIG ID | DIG Info | DIG Name | DIG Functional Class | ||
E0FY2S | DIG Info | Edetate disodium | Complexing agent | ||
E09YYN | DIG Info | Eisenoxyd | Colorant | ||
E0QV0V | DIG Info | Glyceryl palmitostearate | Coating agent ... | ||
E0M1JK | DIG Info | Propylene glycol | Antimicrobial preservative ... | ||
E01UTV | DIG Info | Silicon dioxide | Anticaking agent ... | ||
E0QY1F | DIG Info | Talc | Anticaking agent ... | ||
E05BSD | DIG Info | Titanium dioxide | Coating agent ... | ||
Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM | ||||||
---|---|---|---|---|---|---|
Oxidoreductase (ORase) | ||||||
DBT Name: Albendazole monooxygenase (CYP3A4) | Click to Show/Hide | |||||
Detailed Information | DBT Info click to show the detail info of this DBT | |||||
Experiment (1) for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
Interacting DIG | Propylene glycol | |||||
Biological Activity | Inhibition ratio < 20 % (tested by experiment) | [1] | ||||
Tested Species | Homo sapiens (Human) | |||||
UniProt ID | CP3A4_HUMAN | |||||
Experiment (2) for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
Interacting DIG | Silicon dioxide | |||||
Biological Activity | Protein expression downregulation (tested by experiment) | [2] | ||||
Tested Species | Homo sapiens (Human) | |||||
UniProt ID | CP3A4_HUMAN | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.